Let's hear your thoughts on the latest developments in oncology trials, which trends do you see as most influential in this space?
This content isn’t available here
Access this content and more in the LinkedIn app
Cytel is the world’s leading data-science CRO, driving advancements in human health through robust analytics and innovative clinical trial software. For nearly four decades, we have set the standard in adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. Our mission is clear: accelerate drug development, enhance success rates, and deliver better patient outcomes. With a comprehensive suite of services from innovative trial design to end-to-end biometrics and real-world evidence, our specialized, multidisciplinary team ensures optimal strategies for preclinical research, trial execution, market access, and reimbursement. Headquartered in Cambridge, Massachusetts, Cytel has a global presence with over 2,000 employees across North America, Europe, and Asia. Learn more about how Cytel is harnessing the power of data to advance human health at www.cytel.com.
External link for Cytel
Read the post: https://hubs.ly/Q02SWZMm0 Germany is one of the most attractive markets for #pharmaceutical companies in #Europe. However, navigating the reimbursement landscape can be complex. Dr. Bastian Gaus shares what’s essential for a successful #market entry.
With the industry facing intense financial difficulties, how can pharma companies source quality talent in 2024? Find out today in our free ebook! Download it here: https://hubs.ly/Q02SKxHp0 #ClinicalTrials #Biometrics
Read the post: https://hubs.ly/Q02Sv1yF0 Fixed-sample #clinicaltrial designs may be relatively less complex than other designs, but it remains crucial to maintain the same level of rigor and attention to #statistical design and implementation. Boaz Adler discusses how a #simulation-driven approach can help sponsors avoid inaccuracies and common pitfalls. #biotech #pharma #pharmaceutical #software
Last chance to register for our next webinar! 🚨 Looking for faster development of targeted oncology therapies for specific patient populations? On October 9th, our expert Krishna Padmanabhan will discuss design considerations for adaptive population enrichment trials! 💡 Register here: https://hubs.ly/Q02Sjt0y0 #ClinicalTrials #OncologyTrials
At Cytel we're already excited to meet you all at ISPOR Europe 2024! Be sure to stop by booth 1500 and discover how we empower therapeutic strategies with quantitative excellence! While you're there, meet our colleagues at their HEOR Theatre on AI: "Finally Is Out! What the NICE position on the AI use in evidence generation and synthesis means for HTA Submissions, The Do’s and Don’ts." Book your meeting here: https://hubs.ly/Q02SjtgM0 #ISPOR #HTA #AI
For this weeks quiz, we're diving deeper into the world of rare diseases. 🔎 Currently, there are over 7,000 diseases listed as rare. As medical technology advances, specifically in gene mapping, additional diseases are identified and added to this list every year. Rare disease identification and mapping have also sparked a growing interest in gene editing and personalized medicine, increasingly seen as effective means for treating or even curing these diseases. What do you see as the major challenges in rare disease trials? 🤔 Discover how we can help: https://lnkd.in/eTPMA5j2
This content isn’t available here
Access this content and more in the LinkedIn app
This week was fantastic for us to meet up and connect with our clients. Whether it was during our SCDM exclusive boat tour of the Boston Harbor on Monday or during our exciting East Horizon Launch event in Boston on Wednesday, we’re grateful that we could get your insights and strengthen our collaborations with you! We look forward to many more of these moments to connect with you and strengthen our partnerships! Discover more on East Horizon here: https://bit.ly/4dAZn91 Explore our FSP Services: https://bit.ly/4dti0vu #SCDM2024 #EastHorizon #Boston #FSP
We’re thrilled to share that our colleagues Natalia Mühlemann, Kyle Wathen, and Jan Priel will be instructors for the 2025 UCSF-Stanford CERSI (Center of Excellence in Regulatory Science and Innovation) Bayesian Thinking in Clinical Research Course! 🎉 This course, created by the Medical Outreach Team of the Bayesian Scientific Working Group (BSWG) within the American Statistical Association - ASA Biopharmaceutical Section, is designed for clinical and scientific professionals and covers Bayesian thinking with real-life examples and applications that do not involve mathematics. A unique opportunity to dive into real-life applications shaping the future of drug and biological product development. 🌟 Why learn Bayesian methods? • The Bayesian approach has numerous applications in drug and biological product development. • The FDA is set to release draft guidance on the use of Bayesian methodology in clinical trials by the end of 2025 (PDUFA VII). 🗓 Course Dates: 📅 January 23, 2025 – April 10, 2025 🕙 Thursdays | 10:00 AM – 11:30 AM PT 📍 Virtual 🔗 For more information and registration, click here: https://lnkd.in/ePqZ35SV Don’t miss this chance to learn from the best in the field and stay ahead in clinical research! #BayesianMethods #ClinicalResearch #Biopharma #CERSI #FDA #PDUFAVII
Read the post: https://bit.ly/3TT8YRz Enrichment strategies in #oncology #clinicaltrials have become increasingly important in the era of precision #medicine. Krishna P. discusses how these #adaptive designs can increase efficiency and effectiveness; #FDA guidance; and #statistical challenges. Krishna will be hosting a #webinar on this topic on October 9! Click above to learn more. ☝️